9780 Medical Center Drive
About GlycoMimetics, Inc.
GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.
Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.
231 articles with GlycoMimetics, Inc.
GlycoMimetics, Inc. Awarded National Institutes of Health (NIH) Grant to Study Drug Candidate in Diabetes
Nature Reviews: Drug Discovery Article Describes Design of GlycoMimetics, Inc. Compounds and Newly “Druggable” Disease Targets
Dana-Farber Cancer Institute Presents Results of GlycoMimetics, Inc.'s Lead Drug Candidate in Models of Multiple Myeloma at American Society of Clinical Oncology Annual Meeting
GlycoMimetics, Inc. to Present New Results of Lead Candidate in Additional Animal Models of Sickle Cell Disease at American Society of Hematology Annual Meeting
GlycoMimetics, Inc. to Present Results of Lead Drug Candidate in Animal Models of Sickle Cell Disease at American Society of Hematology Annual Meeting
GlycoMimetics, Inc. Highlights Advances in Lead Drug Candidate for Sickle Cell Patients at International Glycobiology Conference
Tech Council of Maryland Release: Area Life Science Companies Chosen To Make Presentations For Venture Funding At 2005 Mid-Atlantic Bio